Entinostat clinical trials
Also written SNDX-275 and MS-275.
How each study uses entinostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the entinostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
69 studies that test it; most in 2017 (12)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2004 | 2 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 9 |
| 2017 | 12 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 46
National Cancer Institute (NCI) (20) · Syndax Pharmaceuticals (18) · UNC Lineberger Comprehensive Cancer Center (3) · Roberto Pili (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Abramson Cancer Center at Penn Medicine (2) · Taizhou EOC Pharma Co., Ltd. (2) · Tianjin Medical University Cancer Institute and Hospital (2)
Often tested with
Tested in the same studies.
Azacitidine (4) · Bevacizumab (2) · ZEN-3694 (1) · Pembrolizumab (1) · Ipatasertib (1) · Tamoxifen (1) · Abemaciclib (1) · Carboplatin (1)
Related medicines
As reviewed, each with the page that says it.
- One of HDAC inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test entinostat.
- Feb 2027Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailurePhase 1/2 · Tianjin Medical University Cancer Institute and Hospital
- Mar 2027Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene AbnormalitiesPhase 1 · Beijing Tongren Hospital
- Jun 2027Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasPhase 2 · Memorial Sloan Kettering Cancer Center
- Jul 2027Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid TumorsPhase 1/2 · National Cancer Institute (NCI)
- Nov 2027A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyPhase 2 · Zhejiang Cancer Hospital
Studies
Open first, then newest update. How each study uses entinostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 69
- Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene AbnormalitiesRecruitingPhase 1Beijing Tongren HospitalNCT07888114Written as Entinostat
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingPhase 1/2Tianjin Medical University Cancer Institute and HospitalNCT07708194Written as entinostat
- A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07441486Written as Entinostat
- A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyRecruitingPhase 2Zhejiang Cancer HospitalNCT07330544Written as entinostat
- Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder CancerNot yet recruitingPhase 1/2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07261592Written as Entinostat
- A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07235618Written as Entinostat
- INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory MalignanciesRecruitingPhase 1/2University Hospital HeidelbergNCT03838042Written as Nivolumab and Entinostat
- Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02453620Written as Entinostat
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02115282Written as Entinostat
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid TumorsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT05053971Written as Entinostat
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01038778Written as Entinostat
- Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerActive, not recruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT03978624Written as Entinostat
- Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03179930Written as Entinostat
- Entinostat Neuroendocrine (NE) TumorTerminatedPhase 2Antonio FojoNCT03211988Written as Entinostat
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedPhase 1/2Hoffmann-La RocheNCT03280563Written as Entinostat
- Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has SpreadCompletedPhase 1National Cancer Institute (NCI)NCT04631029Written as Entinostat
- A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03250273Written as Entinostat
- Azacitidine and Entinostat in Treating Patients With Advanced Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT01349959Written as Entinostat
- Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating AgentsCompletedPhase 1National Cancer Institute (NCI)NCT02936752Written as Entinostat
- Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)CompletedPhase 1/2Syndax PharmaceuticalsNCT02437136Written as entinostat
See all 69 studies that test entinostat →
Given beside what is tested · 7 — entinostat is usual care or a partner of the new treatment
- A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT04708470Written as Entinostat
- Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.CompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01928576Written as Entinostat
- BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)TerminatedPhase 1National Cancer Institute (NCI)NCT04296942Written as Entinostat
- Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT00387465Written as Entinostat
- MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00462605Written as entinostat
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00313586Written as Entinostat
- MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedPhase 1National Cancer Institute (NCI)NCT00098891Written as entinostat
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
Codes
What other systems call entinostat · ClinicalTrials.gg INT004149
- MeSH (NLM) C118739entinostatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1ZNY4FKK9HENTINOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q1281020entinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1863EntinostatOne source FDA
- DrugBank DB11841One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C118739 | entinostat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1ZNY4FKK9H | ENTINOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q1281020 | entinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1863 | Entinostat | One source FDA |
| DrugBank | DB11841 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.